人参皂苷Rg5通过诱导凋亡抑制原发性肝癌小鼠肿瘤生长  

Ginsenoside Rg5 induces apoptosis and inhibits tumor growth in primary liver cancer mice

作　　者：屈琳琳 刘彦楠 范代娣[1] QU Linlin;LIU Yannan;FAN Daidi(Schoolof Chemical Engineering,Northwest University,Xi’an 710069,China)

机构地区：[1]西北大学化工学院,陕西西安710069

出　　处：《生物加工过程》2023年第5期582-588,共7页Chinese Journal of Bioprocess Engineering

基　　金：国家重点研发计划(2021YFC2101500);国家自然科学基金(22078264、22108224);陕西省自然科学基金青年项目(2023-JC-QN-0109)。

摘　　要：利用二甲基亚硝胺(DEN)和四氯化碳(CCl_(4))诱导的原发性肝癌小鼠模型,采用每天给予100 mg/kg人参皂苷Rg5与阳性药索拉非尼(Sorafenib)进行治疗,通过检测小鼠肝脏肿瘤大小、肿瘤组织病理学切片染色、小鼠血清和肝脏中谷丙转氨酶(ALT)与谷草转氨酶(AST)水平以及小鼠肝脏组织中促凋亡相关蛋白水平,以探究人参皂苷Rg5对小鼠肝脏肿瘤生长的抑制作用及机制。结果表明:人参皂苷Rg5可以显著抑制原发性肝癌小鼠肝脏肿瘤的数量及大小,且与阳性药Sorafenib相比无显著性差异;此外,人参皂苷Rg5改善了原发性肝癌小鼠肝损伤、肝纤维化和肝硬化;在机制方面,人参皂苷Rg5通过诱导细胞凋亡抑制原发性肝癌小鼠肝脏肿瘤生长。本研究结果表明,人参皂苷Rg5可能通过诱导肿瘤细胞凋亡抑制原发性小鼠肿瘤生长,为人参皂苷Rg5用于原发性肝癌的治疗提供理论基础。Ginsenoside Rg5(daily dose of 100 mg/kg)was evaluated,along with the drug Sorafenib,using a mouse model of primary liver cancer induced by dimethylnitrosamine and carbon tetrachloride.The inhibition and mechanism of ginsenoside Rg5 on mouse liver tumor growth were investigated according to the following measurements,including the tumor size,the staining of tumor histopathology section,the alanine aminotransferase(ALT)and aspartate aminotransferase(AST)levels in serum and liver,and the pro-apoptosis related protein levels in liver tissues.As a result,ginsenoside Rg5 could significantly inhibit the number and size of liver tumors in mice with primary liver cancer,without notable difference from Sorafenib.In addition,ginsenoside Rg5 could ameliorate liver injury,liver fibrosis and cirrhosis in primary hepatocellular carcinoma mice.Regarding the action mechanism of ginsenoside Rg5,the induction of apoptosis was likely the major driving force to inhibit liver tumor growth in primary hepatocellular carcinoma mice.Our results provide a new basis for the use of ginsenoside Rg5 to treat primary liver cancer.

关 键 词：人参皂苷Rg5 原发性肝癌 索拉非尼 细胞凋亡 

分 类 号：Q946.83[生物学—植物学] R735.7[医药卫生—肿瘤]